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We recently provided evidence that using the new risk stratification algorithm approach from the 
Canadian Cardiovascular Society (CCS) Guidelines could leave patients with a high 1-year stroke 
rate (4.86 per 100 person-years)1; hence, patients with such high stroke rates are not ‘low risk’, as 
acknowledged by Cairns et al. in their accompanying Editorial2.   
In the 2014 focused guidelines update, the CCS recommends use of the CHADS2 schema referring 
to the original Gage et al publication3 (and thus implying use of a similar definition).  Thus, patients 
with some risk factors already included within the CHA2DS2-VASc score would not have been 
included in the 2014 CCS guidelines. Indeed, it is very important to strictly define the precise 
criteria for providing points related to each component in risk stratification scoring systems, and we 
welcome a clarifying update from the CCS committee on this matter. 
Notwithstanding this inconsistency/misinterpretation on definitions, Cairn et al. raises the concern 
that previous publications using the Danish nationwide registries showed different event rates 
relative to those we presented. However, the devil is in the detail. Different populations and 
inclusion criteria, study settings, definitions on outcomes and time frames may account for the 
variation in event rates seen in various studies (see Online Supplement for full details).   
In an attempt to specify and fully describe our event rates challenged by Cairns et al., we are 
pleased to provide a stratified analysis of 987 patients with prior vascular disease. We defined the 
‘VASc’ component as follows: prior myocardial infarction, prior peripheral artery disease, or aortic 
plaque, as we have done previously4. It is evident that all subgroups of prior vascular diseases carry 
a high one-year thromboembolic event rate, see Table 1. Contrasting low risk CHA2DS2-VASc (that 
is, score 0 (male) or 1 (female)) as a reference population vs those with ≥1 additional stroke risk 
factors (ie. CHA2DS2-VASc score =1 (male) or =2 (females)) to express the hazard attributable to 
vascular disease resulted in a crude HR of 2.7 (95%CI 1.7-4.2). 
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To investigate the subgroup of AF patients with a CHADS2=0 and concomitant MI, we excluded 
those with prior peripheral artery disease and aortic plaque. Contrasting CHA2DS2-VASc=0 (male) 
or 1 (female) as reference population vs CHA2DS2-VASc score =1 (male) or =2 (females) resulted 
in a crude HR of 2.2 (95%CI 1.2-3.8) and1.6 (95%CI 1.0-2.4), for one and five years follow-up, 
respectively. Thus, there is still a relative risk increase in ischemic stroke/SE/TIA in the AF group 
with prior MI.  
Although long follow-up times (i.e. 10 or 12 years) may provide interesting insights into very long-
term outcomes in AF patients, caution is warranted as baseline assumptions (on comorbidity and 
medication use) can be violated  
To conclude, we could perhaps suggest a very simplified risk stratification and thromboprophylaxis 
algorithm based on the approach recommended by the ESC and NICE guidelines (see Online Figure 
S1). By assessing the CHA2DS2-VASc score it is possible to identify the truly low risk patients (0 
(male) or 1 (female)), who do not need any antithrombotic therapy.    
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Table 1: Event rates (per 100 person-years) of ischemic stroke/SE/TIA in 980 AF patients (CHADS2=0) with prior vascular disease 
stratified according to type for 1 and 5 years of follow-up*. 
  1 year of follow-up 5 years of follow-up 
Type of vascular disease Number of 
patients 
Number of events 
/person-time 
Event rate 
(95% CI) 
Number of events 
/person-time 
Event rate 
(95% CI) 
MI 651 12/490 2.5 (1.4-4.3) 23/1,783 1.3 (0.9-1.9) 
Peripheral artery disease 294 6/201 3.0 (1.3-6.7) 13/669 1.9 (1.1-3.4) 
Both MI and peripheral artery 
disease 
35 3/20 15.0 (4.8-46.4) 5/57 8.7 (3.6-21.0) 
*Groups comprising ≤5 patients (e.g. aortic plaque and MI) have been omitted from the table (n=7 patients) 
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We recently provided the evidence that using the new risk stratification algorithm approach from 
the Canadian Cardiovascular Society (CCS) Guidelines could leave patients with a high 1-year 
stroke rate (4.86 per 100 person-years)1; hence, patients with such high stroke rates are not ‘low 
risk’, as acknowledged by Cairns et al. in their accompanying Editorial2.   
In the 2012 CCS guidelines (as in the 2010) it was recommended to use the CHADS2 scoring 
system for risk stratification3; however, the components were defined similarly to those of the 
CHA2DS2-VASc score. The ‘VASc’ component was in combination with female sex triggering a 
recommendation for anticoagulant treatment, but not vascular disease (nor female sex) alone. In the 
2014 focused update, the CCS recommends use of the CHADS2 schema referring to the original 
Gage et al publication4 (and thus implying use of a similar definition).  Thus, patients with some 
risk factors already included within the CHA2DS2-VASc score would not have been included in the 
2014 CCS guidelines. Indeed, it is very important to strictly define the precise criteria for providing 
points related to each component in risk stratification scoring systems, and we welcome a clarifying 
update from the CCS committee on this matter. 
Notwithstanding this inconsistency/misinterpretation on definitions, we would like to specifically 
provide the evidence for a high stroke rate of 4.85 per 100 person-years in AF patients with vascular 
disease as a single risk factor. This corresponds to CHA2DS2-VASc=1 for males and a CHA2DS2-
VASc=2 for females, where our paper reported rates of 4.53 and 5.69, respectively. We defined the 
‘VASc’ component as follows: prior myocardial infarction, prior peripheral artery disease, or aortic 
plaque, as we have done previously5–8.  
Cairn et al. raises the concern that previous publications using the Danish nationwide registries 
showed different event rates relative to those we presented. However, the devil is in the detail. The 
paper by Olesen et al.9 used a combined primary endpoint of ischemic stroke (ICD10: I63; I64), 
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pulmonary embolism (PE) (ICD10: I26) and systemic embolism (SE) (ICD10: I74) or death from 
either of these events (using the Danish Register of Cause of Death 10) and had a different time 
frame, over the period of 1997 to 2006. Different populations and inclusion criteria, study settings, 
definitions on outcomes and time frames may account for the variation in event rates seen in various 
studies.  A recent systematic review shows the accentuated stroke and thromboembolism risk where 
AF is associated with atherosclerotic vascular disease11. 
In a different report, also by Olesen et al.12, AF patients with prior vascular disease were studied. In 
this study peripheral artery disease was somewhat more strictly defined (i.e. leaving out 
atherosclerosis of the aorta (ICD10: I700)). Cairns et al. notes that the event rates, reported in a 
supplementary analysis, for vascular disease were 1.07 % at one year (total of 5 events) and 1.61% 
at 12 years of follow-up (total of 42 events) for patients with a CHA2DS2-VASc =1. However, 
analysing the main results provided in this publication reveals that the thromboembolic event rate of 
2.31% at one year for patients with a CHADS2=0 was primarily affected by patients with peripheral 
artery disease (5.71% and 2.57% for patients with both peripheral artery disease and MI), while 
patients with prior MI (and no peripheral artery disease) displayed a thromboembolic event rate of 
1.79%. The supplementary analysis of patients with a CHA2DS2-VASc=1 (referred to by Cairns et 
al.) included zero events in this subgroup of patients with prior peripheral artery disease; thus the 
event rate of 1.07% for one year was based solely on patients with prior MI. 
Rasmussen et al. 13 also studied the impact of vascular disease in predicting of stroke and death in 
an inception cohort of AF patients. After adjustments for risk factors within the CHADS2 score, the 
adjusted hazard ratio (HR) at one year follow-up for the primary endpoint was 2.51 (95% 
confidence interval [CI] 1.91-3.29) contrasting AF patients with or without (latter being the 
reference population) prior vascular disease. 
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In an attempt to specify and fully describe our event rates challenged by Cairns et al., we are 
pleased to provide a stratified analysis of 987 patients with prior vascular disease (as defined in our 
CCS analysis1 and excluding patients with prior SE or left ventricular dysfunction), see Table 1. It 
is evident that all subgroups of prior vascular diseases carry a high one-year thromboembolic event 
rate. Contrasting low risk CHA2DS2-VASc (that is, score 0 (male) or 1 (female)) as a reference 
population vs those with ≥1 additional stroke risk factors (ie. CHA2DS2-VASc score =1 (male) or 
=2 (females)) to express the hazard attributable to vascular disease resulted in a crude HR of 2.7 
(95%CI 1.7-4.2). 
Of note, the event rate for patients with MI was 1.3 per 100 person-years using 5 years of follow-
up. To investigate this subgroup of AF patients with a CHADS2=0 (defined in accordance with the 
CHA2DS2-VASc components (i.e. no prior SE, left ventricular dysfunction, and age<65 years) with 
prior MI (504 males and 147 females), we excluded those with prior peripheral artery disease and 
aortic plaque. Contrasting CHA2DS2-VASc=0 (male) or 1 (female) as reference population vs 
CHA2DS2-VASc score =1 (male) or =2 (females) resulted in a crude HR of 2.2 (95%CI 1.2-3.8) for 
one year of follow-up, and for five years of follow-up, HR 1.6 (95%CI 1.0-2.4). Thus, there is still a 
relative risk increase in ischemic stroke/SE/TIA in the AF group with prior MI compared to those 
without.  Finally, the high stroke risk associated with females with AF has recently been 
systematically reviewed14, and this accentuated thromboembolic risk would be further accentuated 
in the presence of ≥1 additional stroke risk factors.  
Although long follow-up times (i.e. 10 or 12 years) may provide interesting insights into very long-
term outcomes in AF patients, caution is warranted as baseline assumptions (on comorbidity and 
medication use) can be violated; specifically in this context, the requirement of a non-OAC treated 
cohort with a CHADS2 score =0. As previously1,7, we have attempted to account for this by 
censoring person-time if a prescription of an OAC drug was claimed. By design this will censor 
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some of the studied events, while patients actually treated with OAC will not count in the analysis 
and thereby introduce an unmeasurable bias. In relation to practical use of risk scoring systems for 
stratification on treatment decisions, extensive follow-up times seem less interesting.  
To conclude, we could perhaps suggest a very simplified risk stratification and thromboprophylaxis 
algorithm [Figure S1] based on the approach recommended by the ESC and NICE guidelines where 
the initial step is to identify the low risk patients with CHA2DS2-VASc=0 (male) or 1 (female), who 
do not need any antithrombotic therapy [STEP 1].  Subsequently, we should offer effective stroke 
prevention (which is OAC) to those with ≥1 stroke risk factors [STEP 2].  In Step 2, OAC can be 
with well controlled Vitamin K Antagonist (VKA, with time in therapeutic range >70%) or Non-
VKA oral anticoagulant (NOAC), and the decision to anticoagulate is already made, irrespective of 
CHA2DS2-VASc score.    
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Table 1: Event rates (per 100 person-years) of ischemic stroke/SE/TIA in 980 AF patients with prior vascular disease stratified according 
to type for 1 and 5 years of follow-up*. 
  1 year of follow-up 5 years of follow-up 
Type of vascular disease Number of 
patients 
Number of events 
/person-time 
Event rate 
(95% CI) 
Number of events 
/person-time 
Event rate 
(95% CI) 
MI 651 12/490 2.5 (1.4-4.3) 23/1,783 1.3 (0.9-1.9) 
Peripheral artery disease 294 6/201 3.0 (1.3-6.7) 13/669 1.9 (1.1-3.4) 
Both MI and peripheral artery 
disease 
35 3/20 15.0 (4.8-46.4) 5/57 8.7 (3.6-21.0) 
*Groups comprising ≤5 patients (e.g. aortic plaque and MI) have been omitted from the table (n=7 patients).
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Figure S1: A simple practical algorithm for stroke risk stratification and decision making on 
thromboprophylaxis 
 
